Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients
ASCO 2022: Breast cancer highlights
ASCO 2022: Latest in prostate cancer, including PARP inhibitors
Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma
Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody
CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib
Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone
ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC
Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer
Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas